Spectral Medical Appoints Former FDA Director, Dr. David W. Feigal, Jr., to Its Board of Directors
TORONTO, June 27, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company...
Month: June 2023
ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders
All resolutions were approved.35% of the issued shares represented.MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company...
Assure Holdings Expands Service Offerings to Address the High Growth EEG Services Market
Signs Diagnostics Services Agreement with Neurovative DiagnosticsDENVER, June 27, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”)...
Immutep Completes A$80 Million Capital Raise
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into...
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared...
Emergent BioSolutions Announces CEO Transition
Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE)...
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the...
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing...
Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
Anavex and Partex agreed to enter into a strategic partnership to leverage Partex’s proprietary AI (Artificial Intelligence) technology for Anavex’s...
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide...
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating...
First Wave BioPharma Strengthens Intellectual Property Estate
USPTO and WIPO both publish two adrulipase patent applications for composition of matter and methods of use claims involving new...
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of StudyDSMB Recommendation Allows for...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD)PHILADELPHIA, June...
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on...
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024TORONTO, June 27,...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE...